Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
复制标题
多发性硬化症中血清神经丝光的时间谱：对患者监测的影响。
DOI：
10.1177/1352458520972573
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Plavina T
中科院分区：
文献类型：
--
作者：
Calabresi PA;Arnold DL;Sangurdekar D;Singh CM;Altincatal A;de Moor C;Engle B;Goyal J;Deykin A;Szak S;Kieseier BC;Rudick RA;Plavina T
了解纵向血清神经丝轻链（sNfL）模式如何告知其作为多发性硬化（MS）预后生物标志物的用途，并评估sNfL是否反映MS疾病活动和疾病修饰治疗的使用。这是对复发缓解型MS（RRMS）患者的ADVANCE试验（NCT 00906399）的纵向数据和样本进行的事后分析。sNfL每3个月测量一次，持续2年，然后每6个月测量一次，持续4年。回归模型探讨了sNfL数据如何预测4年的脑体积值、扩展残疾状态量表评分和T2病变。在接受安慰剂、聚乙二醇干扰素β-1a和疾病活动的患者中评估sNfL水平。基线sNfL是4年脑萎缩和新发T2病变的预测因子。与sNfL保持在<16 pg/mL的患者相比，接受聚乙二醇干扰素β-1a治疗的患者在12个月后sNfL降至<16 pg/mL，其临床（p = 0.02）和磁共振成像（MRI）（p < 0.01）结果有所改善。平均sNfL水平在聚乙二醇干扰素β-1a治疗的患者中降低，而在安慰剂治疗的患者中升高（-9.5% vs. 6.8%; p < 0.01）。这些数据支持sNfL作为RRMS的预后和疾病监测生物标志物。
To understand how longitudinal serum neurofilament light chain (sNfL) patterns can inform its use as a prognostic biomarker in multiple sclerosis (MS) and evaluate whether sNfL reflects MS disease activity and disease-modifying therapy usage. This was a post hoc analysis of longitudinal data and samples from the ADVANCE trial (NCT00906399) of patients with relapsing–remitting MS (RRMS). sNfL was measured every 3 months for 2 years, then every 6 months for 4 years. Regression models explored how sNfL data predicted 4-year values of brain volume, expanded disability status scale score, and T2 lesions. sNfL levels were assessed in those receiving placebo, peginterferon beta-1a, and those with disease activity. Baseline sNfL was a predictor of 4-year brain atrophy and development of new T2 lesions. Clinical (p = 0.02) and magnetic resonance imaging (MRI) (p < 0.01) outcomes improved in those receiving peginterferon beta-1a whose sNfL decreased to <16 pg/mL after 12 months versus those whose sNfL remained ⩾16 pg/mL. Mean sNfL levels decreased in peginterferon beta-1a-treated patients and increased in placebo-treated patients (–9.5% vs. 6.8%; p < 0.01). sNfL was higher and more variable in patients with evidence of active MS. These data support sNfL as a prognostic and disease-monitoring biomarker for RRMS.
登录
查看更多内容
DOI：
10.1056/nejmra1401483
发表时间：
2018-01-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Reich DS;Lucchinetti CF;Calabresi PA
通讯作者：
Calabresi PA
影响因子：
9.9
作者：
Lublin FD;Reingold SC;Cohen JA;Cutter GR;Sørensen PS;Thompson AJ;Wolinsky JS;Balcer LJ;Banwell B;Barkhof F;Bebo B Jr;Calabresi PA;Clanet M;Comi G;Fox RJ;Freedman MS;Goodman AD;Inglese M;Kappos L;Kieseier BC;Lincoln JA;Lubetzki C;Miller AE;Montalban X;O'Connor PW;Petkau J;Pozzilli C;Rudick RA;Sormani MP;Stüve O;Waubant E;Polman CH
通讯作者：
Polman CH
影响因子：
29
作者：
Bjornevik, Kjetil;Munger, Kassandra L.;Ascherio, Alberto
通讯作者：
Ascherio, Alberto
影响因子：
11
作者：
Sejbaek, Tobias;Nielsen, Helle Hvilsted;Illes, Zsolt
通讯作者：
Illes, Zsolt
影响因子：
2.6
作者：
Meyer-Moock S;Feng YS;Maeurer M;Dippel FW;Kohlmann T
通讯作者：
Kohlmann T